MeSH D054973 - perivascular epithelioid cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Aadi Bioscience | Sirolimus | Fyarro | 2029-02-14 | 2021-11-22 | ||
| Alkem Laboratories | Sirolimus | Sirolimus | 2021-03-12 | |||
| Amneal Pharmaceuticals | Sirolimus | Sirolimus | 2019-10-18 | |||
| Apotex | Sirolimus | Sirolimus | 2019-10-22 | |||
| CV Sciences | Sirolimus | Rapamune | 1999-09-15 | |||
| Dr Reddys Laboratories | Sirolimus | Sirolimus | 2014-10-27 | |||
| Glenmark Pharmaceuticals | Sirolimus | Sirolimus | 2020-10-16 | |||
| Hetero | Sirolimus | Sirolimus | 2024-09-16 | |||
| MSN Laboratories | Sirolimus | Sirolimus | 2023-01-19 | |||
| Nobelpharma | Sirolimus | Hyftor | 2022-03-22 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
100%3/3
Phase 2
33%3/9
Phase 3
0%0/3
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use